Drug Search Results
More Filters [+]

Zastumotide

Alternative Names: zastumotide, GSK-2132231A, Immunotherapeutic GSK2132231A, MAGE-A3 ASCI
Latest Update: 2020-12-08
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zastumotide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2011-00282

P2

Completed

Melanoma

2018-11-01

NCT00896480

P2

Completed

Melanoma

2014-11-03

PREDICT

P2

Completed

Melanoma

2012-06-27

Recent News Events

Date

Type

Title